11 results
Primary Objective: to derive iPSCs from patients with a variety of diseases caused by genetic mutations or genetic predisposition to disease or of unknown origin. The cells will be propagated and differentiated into a variety of somatic cell types…
The main goal of this study is to investigate whether visual perceptual learning, i.e. practicing a challenging visual task and thereby improving performance, transfers to improved reading and search performance in children with visual impairment.…
To investigate the additional value of partial endothelial trepanation (PET) in a deep anterior lamellar keratoplasty (DALK) procedure in terms of efficacy and safety in patients with keratoconus.
Demonstrate superiority of NEVANAC® (nepafenac ophthalmic suspension) 0.1% relative to nepafenac vehicle based on the percentage of diabetic retinopathy patients who develop macular edema (defined as >=30% increase from pre-operative baseline…
The goal of this study is the development of a clinically verified functional imaging technique of the retina.
To determine the prevalence of disability glare in RP patientsTo identify the origin(s) of disability glare in RP patientsTo establish the clinical value of straylight measurements in RP patients
Measurement of the growth of the eye of children with unilateral cataract.
To evaluate the effect of ISIS 696844 on the rate of change of the area of GA secondary to AMD measured by fundus autofluorescence (FAF)
Primary:To assess the effect of bilateral treatment with AAV5-hRKp.RPGR on functional vision as measured by vision-guided mobility assessment.Secondary:To assess changes after treatment administration in retinal function, functional vision, visual…
Primary: To evaluate the efficacy of QR-110 administered by intravitreal (IVT) injection.Secondary:1. To evaluate the safety and tolerability of QR-110 administered via IVT injection.2. To evaluate changes in patient-reported outcome (PRO) measures…
Primary • To evaluate the efficacy of QR-421aSecondary• To evaluate the safety and tolerability of QR-421a • To evaluate changes in Patient-Reported Outcome (PRO) measures in subjects treated with QR-421a• To evaluate systemic exposure of QR-421a